DAFTAR PUSTAKA

Abbas A., Lichtman A., Pillai S. 2021. Imunologi Dasar Abbas: Fungsi dan Kelainan Sistem Imun. 6th Indonesia edition. Elsevier. p: 207-18.

Achmad D., Panigoro SS., Haryono SJ., et.al. (ed.) 2023. Panduan Tatalaksana Kanker Payudara. Perhimpunan Ahli Bedah Onkologi Indonesia. Ed.3 Jakarta: Peraboi.

Asano Y, Kashiwagi S, Onoda N, et al. 2016. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 23(4):1104-1110. doi:10.1245/ s10434-015-4934-0.

Azab B., et al. 2012. Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients. Ann Surg Oncol: 19(1), 217-24. Doi: 10.1245/s10434-011-1814-0

Barriga V., Kuol N., Nurgali K., Apostolopoulus V., 2019. The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. J. Cancers. 11.1205. http//doi:10.3390/cancers11081205

Borregaard N. 2010. Neutrophils, from marrow to microbes. Immunity. 33:657–70. doi: 10.1016/j.immuni.2010.11.011.

C. Mayer, S. Darb-Esfahani, A.-S. Meyer, K. Hubner, J. Rom, C. Sohn, I. Braicu, J. Sehouli, G. M. Hansch and M. M. Gaida, 2016. Neutrophils Granulocytes in Ovarian Cancer-Induction of Epithelial-to-Mesenchymal-Transition and Tumor Cell Migration," Journal of Cancer, p: 546-554.

Cheang,M. C., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S. & Parker, J. S. 2009. Ki67 index, HER2 status, and prognosis of patientswith luminal B breast cancer. J Nat Can Inst.,101, 736-750.

Chen Ds., Mellman I. 2013. Oncology meets immunology: The cancer-immunity cycle. A Cell Press Journal: Immunity.

Chen J, Deng Q, Pan Y, et al. 2015. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio. 2015;5:502-507. Published 2015 May 12. doi:10.1016/j.fob.2015.05.003.

Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. 2020. Pre-treatment systemic immune- inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 24:2993–3021. doi.org/10.1111/jcmm.14934

Cianfrocca M, Goldstein LJ. 2004. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 9(6):606-616. doi:10.1634/ theoncologist.9-6-606.

Clagnan, W. S., Andrade, J. M., Carrara H., Tiezzi, D., Reis, F., Marana. H. & Abrao, R. 2008. Age as an independent prognostic factor in breast cancer. Rev Bras Ginecol Obstet, 2, 67-74.

Corbeau, I., Jacot, W., & Guiu, S. 2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: A systematic review. Cancers, 12(4). https://doi.org/10.3390/cancers12040958

Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl,S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H. J. & Thurlimann, B. 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Annals of Oncology, 28, 1700–12.

Denkert, C., Sinn, B. V., Issa, Y., Muller, B. M., Maisch, A., Untch, M.., Von Mickwitz, G. & Loibl, S. 2011. Predicton of respons to neoadjuvant chemotherapy: new biomarker approaches and concepts. Breast Care, 6, 265-72.

Desen, W. 2008. Buku Ajar Onkologi Klinis, edisi 2. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia. P: 365-383.

Dong X., Liu C., Yuan J., et.al., 2020. Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocyte and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. Breast Care; 16:328-334. Doi: 10.1159/000509498.

Donskov F, von der Maase H. 2006. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 24(13):1997–2005. doi: 10.1200/JCO.2005.03.9594.

Duffy, MJ. 2013. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract, 22, 4-11.

Edward Chu, M. V. 2019. Cancer Chemotherapy Drug Manual, 2019. United State of America: Jones & Bartlett Learning.

Eisenhauer, E., Therasse, P., Bogaerts, J., Schwartz, L., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S. & Money, M. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1,1). European journal of cancer, 45, p: 228-47.

Fan S., Xie X., Shen Y., Wang W., Gu X., Yao Z. 2022. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers

for early breast cancer patients: A retrospective study. Medicine. 101(32): 1-7.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2018. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin. 68:394-424.

Finn OJ. 2012. Immuno-oncology: understanding the function of the immune system in cancer. Annals of Oncology 23 (supplement B).

Galdiero MR, Bianchi P, Grizzi F, Di Caro G, Basso G, Ponzetta A, Bonavita E, Barbagallo M, Tartari S, Polentarutti N, et al. 2016. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. Int J Cancer. 139(2):446–456. doi: 10.1002/ijc.30076.

Geng SK. et al., 2021. Tumor Infiltrating Neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.BMCcancer.21;68. http://doi.org/10.1186/s12885-021-07789-6.

Gong, C., Yao, H., Liu, Q., Chen, J., Shi, J., Su, F. & Song, E. 2010. Markers of tumor-initiating cells predict chemoresistance in breast cancer. Plos one, 5, e15630.

Granot Z,2019.Neutrophils as a Therapeutic Target in Cancer. Front Immunol [Internet]. ;10:1710. Available from: https://pubmed.ncbi.nlm.nih.gov/31 37988.

Graziano V, Grassadonia A, Iezzi L, et al. 2018. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 44:33-38. doi:10.1016/j.breast.12.014.

Gregory AD, Houghton AM, 2011 Tumor-associated neutrophils: new targets for cancer therapy. CancerRes.71(7):2411–2416.doi: 10.1158/0008-5472.CAN-10-].

Gucalp, A., Gupta, G.P., Pilewskie, M.L., Sutton, E.J. & Norton, L. 2014. Advances in managing breast cancer: a clinical update. F1000prime reports, 6.

Hanahan D, Weinberg RA., 2011. Hallmarks of cancer: the next generation. Cell. 144(5):646–674. doi: 10.1016/j.cell.2011.02.013.

Jacqueline C., Bourfia Y., Hbid H., Sorci G., Thomas F., Roche B. 2016. Interaction between immune challanges and cancer cells proliferation: timing does matter! Evolution, Medicine and Public Health.

Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H.2009. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 27(28):4709–4717. doi: 10.1200/JCO.2008.18.9498.

Kawahara R., Shiozawa Y., 2015. Hematopoiesis Reference Module in Biomedical Research. Elsevier. http://dx.doi.org/10.1016/B978-0-12-801238-3.05054-6.

Kawahara T, Furuya K, Nakamura M, Sakamaki K, Osaka K, Ito H, Ito Y, Izumi K, Ohtake S, Miyoshi Y, et al. 2016. Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. BMCCancer. 16:185.doi:10.1186/s12885-016-2219- z.

Kresna SB. 2012. Angiogenesis dan Metastasis. In: Ilmu Dasar Onkologi ed.3. Fakultas Kedokteran Universitas Indonesia, p: 220-53.

Kresna SB. 2018. Imuno-Onkologi ed.1. CV. Sagung. p: 3-127.

Kumar V., Abbas A., Aster J. 2015. Robbin and Cotran Pathologic Basis of Disease.Elsevier.

Lei S, Zheng R, Zhang S,Wang S, Chen Ru, Sun K, et al. 2021. Global patterns of breast cancer incidence and mortality: Apopulation-based cancer registry data analysis from 2000 to 2020.Cancer Commun. 41:1183 1194.https://doi.org/10.1002/cac2.12207

Lester SC., 2010. The Breast in Text book of Robbin's Pathologic Basic of Disease; Chapter 23. 8th Ed. Phil. W.B Saunders Co. p: 1083-90.

Li QQ., Chen ZQ., Cao XX., et al. 2011. Involvement of NF-kB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells; Cell Death and Differentiation 18, 16-25. https://doi:10.1038/cdd/2020.103.

Liang W., Ferrara N., 2016. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis. Cancer Immunology at the Crossroads: Tumor Microenvironment. American Association for Cancer Research Journal. https://doi.org/10.1158/2326-6066.CIR-15-0313.

Licciulli S. 2022. New Dimensions in Cancer Biology: Updated Hallmarks of Cancer Published. American Association for Cancer Research.

Lin F., et al. 2022. Pan-Immune-Inflamation Value: A New Prognostic Index in Operative Breast Cancer. Frontiers in Oncology,12. https://doi.org/10.3389/fonc.2022.830138

Litiere S, Collette S, de Vries EG, Seymour L, Bogaerts J. 2017. RECIST - learning from the past to build the future. Nat Rev Clin Oncol ;14(3):187–192. doi: 10.1038/nrclinonc.2016.195.

Liu C, Xing H, Guo C, Yang Z, Wang Y, Wang Y. 2019. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF- 1 signaling pathways. Cell Cycle. 18(18):2215-2227. doi:10.1080/15384101. 2019.1638182.

Lukasiewicz S. et.al., 2021. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategis AnUpdatedReview.Cancers,13,4287:
https://doi.org/10.3390/cancers13174287

Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020;18(1):33. Published 2020 Feb 28. doi:10.1186/s12964-020-0527-z.

Masucci MT, Minopoli M, Carriero MV. 2019. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. FrontOncol. 9:1146. https://doi.org/10.3389/fonc.2019.01146.

Mehraj U, Hamid AD, Wani NA, Mir MA. Tumor microenvironment promotes breast cancer chemoresistance Cancer Chemotherapy and Pharmacology https://doi.org/10.1007/s00280-020-04222-w.

Mendoza-Rodríguez M, Arévalo Romero H, Fuentes-Pananá EM, Ayala-Sumuano JT, Meza I. 2017. IL-1β induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells. Cancer Lett.;390:39-44. doi:10.1016/j.canlet.01.005.

Menen, R. S. & Teshome, M. 2019. Invasive Breast Cancer. Dalam : Feig, B. W.& Ching, C. D.The MD Anderson surgical oncology handbook. 6thed. Philadelphia, Wolters Kluwer, 67-127.. J Intern Med: 279:541-562.

Montagut C, Tusquets I, Ferrer B, et all. 2006. Activation of nuclear factor-k B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocrine-Related Cancer. 13;p: 607–16.

Oluogun WA, Adedokun KA, Oyenike MA, Adeyaba OA. 2019. Histological classi cation, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10- year retrospective study. Int J Health Sci.3(4); 3-9.

Page, R. & Takimoto, C. 2001. Principles of chemotherapy. Cancer management: a multidisciplinary approach, 5th ed. Melville, NY: PRR, Inc. 20-31.

Peng Y. Chen R. Qu F., et.al. 2020. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients. Cancer Biology &TherapyVol.21,No.2,189http://doi.org/10/1080/15384047.2019.16800

Powell DR., Huttenlocher A. 2016. "Neutrophils in the Tumor Microenvironment," Neutrophils in Action, p. 1, 2016.

Prakosa YW. 2022. Dasar-Dasar Imunologi Tumor. Penerbit Airlangga University Press. Surabaya.

Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T. & Martin, M. 2011. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. Journal of Clinical Oncology, (29), 859- 67.

Prihantono et.al., 2023. Cancer Insidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review: Ethiopian Journal of Health Science: 33(3): 515-522; doi: 10.4314/ejhs.v33i3.15

Prosnitz LR, Iglehart JD, Winer EP. Breast Cancer. 2001. In : Rubin P, editors. Clinical Oncology, A Multidisciplinary Approach for Physicians and Students, 8th ed.WB Saunders Co. p: 267-96.

Qu X, Tang Y, Hua S. 2018. Immunological approaches towards Cancer and inflammation:acrosstalk. FrontImmunol. ;9:563.doi: 10.3389/fimmu.201 8.00563.

Qu Y, Dou B, Tan H, Feng Y, Wang N, Wang D. 2019. Tumor microenvironment-driven non- cell-autonomous resistance to antineoplastic treatment. Mol Cancer 18(1):69. Published 2019 Mar 30. doi:10.1186/s12943-019-0992-4.

Querol EU. , Rosales C. 2015, "Neutrophils in Cancer: Two Sides of the Same Coin," Journal of Immunology Research, p. 1, 2015.

Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoen, J. L., Vogel, V. G. & Dakhil, S. R. 2008. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27.Journal of Clinical Oncology, 26, 778-85.

Rosen PP.2009. Rosen's Breast Pathology 3rd Ed. Assesment of Prognosis, Morphologic Prognostic Markers, and Tumor Growth Rate. Chapter 12. Philadelphia. p 373- 74.

Sahin AB., et al. 2021. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Nature scientificreports.11:14662. https://doi.org/10.1038/s41598-021-94184-7

Sainsburry, Anderson TJ, Morgan DAL. Breast Cancer. BMJ, 2000: 321; p: 745-51.

Sampepajung, D. 2010. Kanker payudara di Indonesia, masalah dan penanggulangannya. Naskah pidato pada acara pengukuhan sebagai guru besar bidang ilmu bedah onkologi Fakultas Kedokteran Universitas Hasanuddin, Makassar, 27 Desember 2010.

Shaul ME, Fridlender ZG. 2017. Neutrophils as active regulators of the immune system in the tumor microenvironment. J Leukoc Biol. 102(2):343–349.doi: 10.1189/jlb.5MR1216-508R.

Shaul ME, Fridlender ZG. 2018. Cancer-related circulating and tumor-associated neutrophils- subtypes,sources and function. FEBS J. 285(23):4316–4342. https://doi.org/10.1111/febs.14524.

Shen M.et.al., 2014. Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis: Plos One

Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA., Coebergh JW. 2008. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 107:309–330 DOI 10.1007/s10549-007-9556-1.

Solorzano CC, Ahearne PM, Leach SD. Invasif Breast Cancer. In : Berger DH, Feigh BW, Fuhrman, editors. 2003. The MD Anderson Surgical Oncology Handbook, 3th ed. Lippincott Williams and Wilkins. p: 14-28.

Stanton SE, Disis ML. 2016. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. Journal for ImmunoTherapy of Cancer;4:59. doi: 10.1186/s40425-016-0165-6.

Sudarsa, I., Manuaba, I., Maliawan, S., Sutirtayasa, I. 2016. High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein expression as negative predictive factor for combined neoadjuvant chemotherapy in young age stage III breast cancer. Bali Medical Journal. 5(2). p226-236. DOI:10.15562/bmj. v5i2.207.

Sukardja IDG. 2000. Etiologi Kanker dalam Onkologi Klinik, Edisi 2, Airlangga University Press, Surabaya. p: 113-25.

Sung H., et al. 2021. Global Cancer Statistics 2020 : Globocan Estimates of Incidence and Mortality Worldwide for 36 cancer in 185 countries. Cancer Journal for Clinicians,71(3):209-249.Available at:https://doi.org/10.3322/caac.21600.

Suyatno, Pasaribu ET, 2014. Bedah Onkologi Diagnosis dan Terapi ed.2. Jakarta. CV. Sagung Seto, p. 39-86.

Templeton AJ, et al., 2014. Prognostic Role of Neutrophil-to-lymphocyte Ratio in Solid Tumors: A Systemic Review and Meta Analysis. J Natl Cancer Inst; 106 (6): dju124 doi:10.1093/jnci/dju124.

Trellakis S, Farjah H, Bruderek K, Dumitru CA, Hoffmann TK, Lang S, Brandau S. 2011. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol. 24(3):683–693. doi: 10.1177/039463201102400314.

Uribe-Querol E, Rosales C. 2015. Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res. 2015:983698. doi:10.1155/2015/983698.

Vano YA, et al., 2018. Optimal cut-off for neutrophil-to-lymhocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patient: Plos one: http://doi.org/10.1371/journal.pone.0195042.

Vincent T. De Vita, E. C. 2008. Principles Of Cancer Chemotherapy. In: Edward Chu, V. T. D. V. (ed.). Physicians cancer chemotherapy drug manual. Massachusetts: Jones and Bartlett. 34-42.

Wang J, et al., 2018. Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary c ancer. Cancer Sci.;109(7):2266– 2274.doi: 10.1111/cas.13627.

Wang Y, Chen J, Yang L, Li J, Wu W, Huang M, Lin L, Su S. 2019. Tumor-contacted neutrophils promote metastasis by a CD90-TIMP-1 Juxtacrine-paracrine loop. Clin Cancer Res. 2019;25(6):1957–1969. doi: 10.1158/1078-0432.CCR-18-2544.

Wang, M., Hou, L., Chen, M. et al. 2017. Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer. Sci Rep 7, 44673 ;https://doi.org/10.1038/srep44673.

Westerblad, H., Clair, D. K. S., Reid, M. B., Gilliam, L. A., Ferreira, L. F., Bruton, J. D. & Moylan, J. S. 2011. Doxorubicin acts through tumor necrosis factor. J Appl Phisiol,110, 935-42.

Wihandani D, Adiputra P, Supadmanaba I. 2017. Low prevalence of Caveolin-1 oncogenic polymorphism G14713A and T29107A among breast cancer patient in Sanglah General Hospital. Bali Medical Journal. 6(3): S109-S112. DOI:10.15562/bmj.v6i3.743.

Wu L, Saxena S, Awaji M, Singh RK. 2019. Tumor-Associated Neutrophils in Cancer: Going Pro. Cancer: 11,564; doi:10.3390/cancers11040564.

Wu L, Saxena S, Awaji M, Singh RK. 2019. Tumor Associated Neutrophils in Cancer: Going Pro. Cancers (Basel). 11(4):564. Published 019 Apr 19. doi:10.3390/cancers11040564

Y. Yang, Y. Yang, J. Yang, X. Zhao and X. Wei,.2020. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Frontiers in Cell and Developmental Biology, vol. 8, p. 758.

Yang G., et.al. 2022. Novel Peripheral Blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer. Frontiers in Surgery. 9:1004687. doi: 10.3389/fsurg.2022.1004687

Yao, L., Liu, Y., Li, Z. Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T. & Lin, B. 2011. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Annals of Oncology, 22, 1326-31.

Yuka Asano et. al., 2018. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes. ANTICANCER RESEARCH 38: 2311-2321

Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J, Sun Y. 2018. Tumor-infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric Cancer. Ann Surg. ;267(2):311– 318.
doi: 10.1097/SLA.0000000000002058.

Zhou Qing, et al., 2021. Role of Neutrophil-to-lymphocyte Ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta- analysis.BMJOpen: 11:e047957.doi:10.1136/bmjopen-2020-047957.

Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. 2015. Type I interferons in anticancer immunity. Nat Rev Immunol;15(7):405- 414.
doi:10.1038/nri3845.

No	Usia (Tahun)	Grade	Ukuran Tumor (cm)		Respon Kemoterapi	NRL		TAN	Regimen Kemoterapi
			Sebelum	Sesudah		Sebelum	Sesudah		
1	63	III	11	7	Respon	2,65	0,34	Low	TAC
2	54	II	9	4,5	Respon	1,75	6,41	High	TAC
3	42	III	21	7,3	Respon	8,68	7,66	High	TAP
4	46	II	17	6.5	Respon	5,53	1,80	High	TAC
5	43	II	9	5	Respon	6,46	8,67	High	TAC
6	56	III	19	3	Respon	0,92	4,19	High	TAC
7	72	III	27	12	Respon	7,3	1,33	High	TAP
8	43	III	25	21	Respon	7,21	6,58	High	TA
9	38	II	6,8	4,5	Respon	1,90	4,27	High	TAC
10	45	II	6	3	Respon	2,10	3,84	Low	CAF
11	44	III	18	7,5	Respon	2,57	2,64	High	TAP
12	47	II	8	6	Respon	1,95	0,17	High	TAP
13	47	III	20	18	Respon	4,64	1,85	High	TAP
14	73	III	10	4,5	Respon	1,51	0,45	High	TAC
15	65	III	18	7,3	Respon	3,32	5,30	High	TAP
16	35	III	8	6	Respon	2,57	3,21	High	TAP
17	51	I	14	7	Respon	1,81	0,75	Low	TAC
18	41	III	24	7	Respon	2,92	12,6	High	AC
19	51	III	5,5	3,3	Respon	9,72	3,48	High	TAC
20	47	III	6	4	Respon	3,28	1,78	High	TA
21	37	II	8,5	4	Respon	4,97	2,11	High	TA
22	41	II	7,5	3,5	Respon	1,67	3,68	High	TA
23	43	II	3,2	0	Respon	2,42	0,08	High	TAC
24	68	II	20	9	Respon	1,37	1,31	High	TA
25	50	III	10	7	Respon	2,32	9,11	High	TAC
26	53	II	5	1,5	Respon	4,12	0,40	Low	TAC
27	27	I	18	5	Respon	2,36	3,64	High	TAC
28	38	II	12	7	Respon	24,1	9,67	High	TA
29	61	II	10	3,5	Respon	1,57	1,13	High	TAP
30	49	III	25	17	Respon	2,72	0,88	High	TAP
31	49	II	22	7	Respon	1,63	1,25	High	TAC
32	49	I	8	6	Non respon	1,15	0,38	Low	TAC
33	43	II	12	8	Respon	2,57	1,85	High	TAP

34	44	III	5	2	Respon	1,24	1,28	High	TAC
35	42	II	12	4	Respon	2,02	2,99	High	TAC
36	66	III	15	4	Respon	1,70	0,68	Low	TAP
37	53	III	15	7	Respon	1,70	5,56	High	TAC
38	52	III	4.6	4	Non respon	2,03	1,57	Low	TA
39	48	II	15	15	Non respon	4,44	11,9	High	TA
40	64	II	5.5	9	Non respon	3,53	7,74	Low	TAC
41	59	II	3	1	Respon	0,54	0,54	High	TA